You just read:

Egalet Announces Positive Top-Line Results from Phase 3 Study Evaluating Efficacy and Safety of Egalet-002 in Patients with Moderate-to-Severe Chronic Low Back Pain

News provided by

Egalet Corporation

Nov 28, 2017, 05:02 ET